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INVITED COMMENTARY
Thomas F. Lindsay, MD, Toronto, Ontario, Canada
Protection of tissues from ischemic tissue damage by short
periods of ischemia, termed ischemic preconditioning (IP), was
described more than 15 years ago. Despite many animal experi-
ments that suggest that IP can significantly improve tissue viability
after ischemia and thousands of citations in PubMed, it has yet to
become part of the standard of care in vascular, cardiac, plastic, or
transplant surgery, where tissues are predictably rendered ischemic
and reperfused.
This experimental study in rats demonstrates the protection of
specific mitochondrial enzyme complexes in muscles pretreated
with three 10-minute cycles of ischemia and 10 minutes of reper-
fusion before a 5-hour period of ischemia. The protection de-
scribed was measured 5 minutes after reperfusion. These data in
skeletal muscle further refines our knowledge with respect to the
biochemical pathways that mediate this protection. Key unan-
swered questions include: Does this protection persist hours to
days later? Can IP improve muscle function or limb salvage that is
clinically measurable? These answers are relevant to surgeons and
their patients.
Vascular surgical procedures frequently induce muscle isch-
emia during elective surgical reconstructions but the duration of
ischemia is relatively short and usually well tolerated; thus, precon-
ditioning is rarely required. However, the more challenging clini-
cal situations are those where acute profound limb/muscle isch-
emia develops secondary to embolus, trauma, or thrombosis. In
these settings, no opportunity for muscle preconditioning is pos-
sible. This may in part account for the severe muscle injury that
frequently develops in these clinical scenarios. The ability to em-
ploy IP may be limited in vascular surgery but may be most useful
in transfer of free muscle flaps.
An area where IP may have much greater application to
vascular surgery would be in cardiac protection induced by remote
muscle ischemia. A recently published clinical trial in children used
intermittent leg ischemia before cardiac surgery and demonstrated
reduced troponin I release, decreased inotropic support require-
ments, and reduced cytokine levels postoperatively.1 If induction
of brief periods of skeletal muscle ischemia before elective vascular
surgical procedures would provide cardiac protection, this would
be a tremendous advance because myocardial infarction and other
cardiac complications are the principal cause of morbidity and
mortality after vascular surgery.
This article has provided biochemical evidence of the pathways
protected by IP in skeletal muscle. Further research will continue
to refine the exact pathways involved; however, more study is
required to determine the longer-term effectiveness of IP and its
applicability to common clinical situations where it may have
considerable impact.
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